ArticleJournal of gastrointestinal cancer2026
Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatic arterial infusion pump (HAIP) therapy is a promising treatment for metastatic colorectal cancer (mCRC) with liver metastases, delivering targeted therapy to improve efficacy and reduce systemic toxicity. This retrospective study evaluates HAIP outcomes at an academic center and safety net hospital.
methodsPatients with mCRC and liver metastases receiving at least one HAIP floxuridine (FUDR) cycle in combination with systemic chemotherapy (SCT) from 2013 to 2023 were included. Baseline data on demographics, tumor characteristics, and prior treatments were collected. The primary outcome was overall survival (OS) post-pump placement, with secondary outcomes of real-world progression-free survival (rwPFS) —defined as the time from HAIP placement to radiographic disease progression or death— and HAIP-related complications.
resultsOf 88 patients assessed, 63 met inclusion criteria. Median age was 46 years (IQR 41–57); 54% were male. Prior to HAIP, 60% (n = 38) received one line of systemic chemotherapy (SCT), and 29% (n = 18) received two. Median OS was 38.0 months (95% CI 21.9–not reached), and median rwPFS was 11.2 months (95% CI 7.1–16.1). Univariate analysis linked baseline bilirubin, KRAS mutation, and CEA levels to OS. However, only elevated baseline bilirubin remained an independent predictor of worse survival in the final multivariate model. Common complications were hematoma (6.4%, n = 4) and pump infection (3.2%, n = 2). Grade 3 FUDR toxicities were rare: elevated alkaline phosphatase (n = 6), AST/ALT (n = 3), bilirubin (n = 2), and thrombocytopenia (n = 1).
conclusionsHAIP treatment with FUDR is an effective treatment option for patients with mCRC and hepatic metastasis. HAIP treatment is associated with enhanced survival outcomes and limited rates of complications. Prospective, randomized studies are needed to confirm HAIP’s role in mCRC management.
Indexed as
Identifiers
41563534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.